A61K47/58

ANTIMICROBIAL NANOWORMS
20220331262 · 2022-10-20 ·

At least one nanoworm comprises a plurality of alkene units and a plurality of macroCTA polymer units. The macroCTA polymer units include R.sup.1 groups from reversible addition-fragmentation chain-transfer agents. In certain aspects, the R.sup.1 groups of the macroCTA polymer units are functional groups, such as a carboxylic acid, an alkyne, a pyridine, a dopamine, a thiolactone, a biotin, an azide, a peptide sequence, a sugar sequence, a protease, a glycanase, a polymer, other functional groups, and combinations thereof. In certain aspects, the macroCTA polymer units comprise quaternized amines, In certain aspects, the macroCTA polymer units comprise functionalized quaternized amines, such as an alkyl group, a carboxylic acid, an alkyne, a pyridine, a dopamine, a thiolactone, a biotin, an azide, a peptide sequence, a sugar sequence, a protease, a glycanase, a polymer, other functional groups, and combinations thereof. In certain aspects, the coating comprises the at least one nanoworm.

ANTIMICROBIAL NANOWORMS
20220331262 · 2022-10-20 ·

At least one nanoworm comprises a plurality of alkene units and a plurality of macroCTA polymer units. The macroCTA polymer units include R.sup.1 groups from reversible addition-fragmentation chain-transfer agents. In certain aspects, the R.sup.1 groups of the macroCTA polymer units are functional groups, such as a carboxylic acid, an alkyne, a pyridine, a dopamine, a thiolactone, a biotin, an azide, a peptide sequence, a sugar sequence, a protease, a glycanase, a polymer, other functional groups, and combinations thereof. In certain aspects, the macroCTA polymer units comprise quaternized amines, In certain aspects, the macroCTA polymer units comprise functionalized quaternized amines, such as an alkyl group, a carboxylic acid, an alkyne, a pyridine, a dopamine, a thiolactone, a biotin, an azide, a peptide sequence, a sugar sequence, a protease, a glycanase, a polymer, other functional groups, and combinations thereof. In certain aspects, the coating comprises the at least one nanoworm.

Methylphenidate extended release chewable tablet
11633389 · 2023-04-25 · ·

An oral methylphenidate extended release tablet is described, which can be scored and still retain its extended release profile. The tablet contains a combination of an uncoated methylphenidate-ion exchange resin complex, a barrier coated methylphenidate-ion exchange resin complex-matrix, and an uncomplexed methylphenidate active component. Following administration of a single dose of the extended release methylphenidate chewable tablet, a therapeutically effective amount of methylphenidate is reached in less than about 20 minutes and the composition provides a twelve-hour extended release profile.

Polymer materials for delivery of short-chain fatty acids to the intestine for applications in human health and treatment of disease

Provided herein are polymer materials that find use in, for example, delivery of short-chain fatty acids. In particular, polymers are provided that form stable nanoscale structures and release their payload, for example, by cleavage of a covalent bond (e.g., via hydrolysis or enzymatic cleavage). The polymers are useful, for example, for delivery of payloads (e.g., SCFAs) to the intestine for applications in health and treatment of disease, and have broad applicability in diseases linked to changes in the human microbiota including inflammatory, autoimmune, allergic, metabolic, and central nervous system diseases, among others.

Polymer materials for delivery of short-chain fatty acids to the intestine for applications in human health and treatment of disease

Provided herein are polymer materials that find use in, for example, delivery of short-chain fatty acids. In particular, polymers are provided that form stable nanoscale structures and release their payload, for example, by cleavage of a covalent bond (e.g., via hydrolysis or enzymatic cleavage). The polymers are useful, for example, for delivery of payloads (e.g., SCFAs) to the intestine for applications in health and treatment of disease, and have broad applicability in diseases linked to changes in the human microbiota including inflammatory, autoimmune, allergic, metabolic, and central nervous system diseases, among others.

FREE-STANDING NON-FOULING POLYMERS, THEIR COMPOSITIONS, AND RELATED MONOMERS

Free-standing non-fouling polymers and polymeric compositions, monomers and macromonomers for making the polymers and polymeric compositions, objects made from the polymers and polymeric compositions, and methods for making and using the polymers and polymeric compositions

FREE-STANDING NON-FOULING POLYMERS, THEIR COMPOSITIONS, AND RELATED MONOMERS

Free-standing non-fouling polymers and polymeric compositions, monomers and macromonomers for making the polymers and polymeric compositions, objects made from the polymers and polymeric compositions, and methods for making and using the polymers and polymeric compositions

GLYCOTARGETING THERAPEUTICS
20230119325 · 2023-04-20 ·

Several embodiments of the present disclosure relate to therapeutic compositions configured to target the liver of a subject and that are useful in the treatment or prevention of one or more of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent. In several embodiments, the compositions are configured to target the liver and deliver antigens to which tolerance is desired. In several embodiments, the compositions are configured for clearance of a circulating protein or peptide or antibody associated with one or more of the above-mentioned maladies. Methods and uses of the compositions for induction of immune tolerance are also disclosed herein.

GLYCOTARGETING THERAPEUTICS
20230119325 · 2023-04-20 ·

Several embodiments of the present disclosure relate to therapeutic compositions configured to target the liver of a subject and that are useful in the treatment or prevention of one or more of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent. In several embodiments, the compositions are configured to target the liver and deliver antigens to which tolerance is desired. In several embodiments, the compositions are configured for clearance of a circulating protein or peptide or antibody associated with one or more of the above-mentioned maladies. Methods and uses of the compositions for induction of immune tolerance are also disclosed herein.

COMPOUNDS FOR THE INDUCTION OF ANTIGEN-SPECIFIC IMMUNE TOLERANCE
20230069712 · 2023-03-02 ·

Disclosed are compounds for the induction of antigen-specific immune tolerance in a subject, the compounds comprising an antigen, a polymeric linker and a liver targeting moiety, wherein the polymeric linker comprises a terminal end unit lacking each of a dithioester and a dithiobenzoate and wherein the terminal end unit confers improved stability to the compound when in solution.